What Пентаса Treats: Main Uses and Benefits

The medication is commonly used to help with certain chronic inflammatory conditions of the bowel. It is applied across domains where the goal is to support the body in managing inflammatory processes within the digestive tract, including the effort to achieve and sustain remission.

---

Inducing and Maintaining Inactivity

This treatment is used in situations involving certain distressing symptoms during periods of mildly to moderately active disease, particularly Ulcerative Colitis. It helps address symptom clusters that become more disruptive during flare-ups, such as rectal bleeding, urgency, and symptoms related to gastrointestinal distress. It is applied across domains characterized by active episodes and the need for supportive management aimed at reducing the occurrence of subsequent episodes.

Its application during these phases is relevant when supportive symptom management is appropriate, as it may assist with maintaining functional stability and helps patients cope more steadily with symptom fluctuations. This medication contributes to easing the overall symptom load.

---

Quick Fact: Managing Inflammatory Symptoms

The primary therapeutic focus is on managing symptoms related to inflammatory or irritative states in the bowel, which supports the body in its effort to achieve and sustain disease inactivity (remission). This continuous use may assist with reducing the occurrence of subsequent episodes, contributing to improved comfort and supporting a sense of stability for patients.

Who can and cannot use Пентаса?

The eligibility for using Пентаса (Mesalazine) is strictly defined by regulatory authorities based on a patient’s age, pre-existing health conditions, and specific medical history.

---

Absolute Contraindications (Must Not Use)

Condition/Population	Restriction	Authority Basis
Hypersensitivity	Known or suspected allergy to mesalazine, salicylates, or any excipients in the product.	FDA/SmPC
Organ Failure	Patients with severe hepatic impairment or severe renal impairment.	SmPC
Age	Children under the age of 2 years.	SmPC
Comorbidity	Patients with an active peptic ulcer or a coagulopathy (bleeding disorder).	SmPC

---

Conditional Use and Restrictions ️

Caution and close monitoring are required for patients with the following conditions, as stated in official labeling:

• Impaired Renal/Hepatic Function: Use is not recommended in general renal impairment, and both liver and kidney function must be assessed prior to and periodically during therapy.
• Asthma/Pulmonary Disease: Patients with pre-existing pulmonary disease, particularly asthma, require very careful monitoring during treatment.
• Pediatric Use: Safety and effectiveness for the oral formulation have not been established in pediatric patients (under 18 years) in the US. In other regions, use is contraindicated under age 2.
• Pregnancy/Lactation: Use is restricted and requires a physician's formal risk-benefit assessment, as Mesalazine is excreted in breast milk and human studies are limited.

Interactions with other medicines and products

The following clinically significant interactions with mesalamine (the active ingredient in Pentasa) are documented in official regulatory information. Concomitant use with other medications may require increased monitoring or dose adjustments.

Pharmacodynamic Interactions

Interacting Product Category	Interaction Description	Monitoring Requirement
Purine Analogs (e.g., Azathioprine, 6-Mercaptopurine)	Increased risk of myelotoxicity (blood disorders), potentially due to effects on drug metabolism.	Monitor complete blood cell and platelet counts.
Nephrotoxic Agents (including NSAIDs)	Increased risk of nephrotoxicity (kidney damage).	Monitor renal function (kidney tests) regularly.
Coumarin-type Anticoagulants	May affect the anticoagulant activity.	Monitor coagulation parameters (e.g., INR).

Exposure and Testing Considerations

Certain pH-modifying agents may alter the release profile or exposure of some mesalamine formulations. Lactulose or similar preparations may also inhibit mesalamine release in the colon.

Interference with Laboratory Tests

Mesalamine use may lead to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection. An alternative assay should be considered when this test is performed.

Patients with known renal or hepatic impairment are considered a specific population requiring evaluation of risks and benefits when considering these potential interactions.

The pharmacodynamic action of Mesalazine (5-Aminosalicylic Acid/5-ASA) is highly localized, relying on its direct presence within the intestinal lining to modulate chronic inflammation through several simultaneous mechanisms. The mechanism is fundamentally defined by the requirement that the drug concentrates at the mucosal surface.

Mesalazine acts as a reversible inhibitor of key enzymes in the Arachidonic Acid Cascade, specifically Cyclooxygenase (COX) and 5-Lipoxygenase (5-LOX). Inhibition of these enzymes reduces the synthesis and release of pro-inflammatory mediators, such as prostaglandins and leukotrienes (e.g., LTB4). This initial step contributes to the attenuation of inflammatory signals in the tissue.

Simultaneously, the molecule interferes with the activation of the Nuclear Factor-kappa B (NF-κB) transcription factor, a central component in the cellular signaling responsible for the genetic production of pro-inflammatory cytokines like TNF-alpha and IL-1beta. This cellular action contributes to the modulation of immune cell signaling in the gut wall.

A third mechanism involves Mesalazine’s function as a free radical scavenger and antioxidant. It directly neutralizes highly reactive oxygen species (ROS) produced by active immune cells, thereby limiting the collateral damage to the intestinal lining and contributing to the stabilization of the local inflammatory cascade.

The administration of Pentasa is officially established through two primary routes: oral (using extended-release capsules, tablets, or granules) and rectal (using suppositories or enemas) to deliver the active ingredient directly to the inflamed intestinal lining. The official usage guidelines outline distinct dosing regimens depending on the clinical objective. For the induction of remission during acute, active disease, the standard oral regimen involves a total daily dose of up to 4 g of mesalazine. This quantity is typically taken in divided doses (e.g., two to four times daily) to maintain a steady concentration of the active component.

Following successful induction, the treatment transitions to a long-term maintenance phase, where the total daily dose is reduced, such as to 2 g, which may be administered once daily or in divided doses. Rectal administration, utilizing the 1 g dose, is generally reserved for local action in the distal colon and is often recommended for use at bedtime to ensure optimal retention.

The prolonged-release oral forms are subject to critical handling instructions to preserve their delivery profile: the capsules and tablets must not be crushed or chewed. If not swallowed whole, the contents of capsules or granules can be sprinkled onto soft food like applesauce or yogurt and must be consumed immediately with adequate fluid intake. Dosing for pediatric patients aged six and older is calculated based on body weight, and the medicine is not recommended for use in cases of severe hepatic or renal impairment.

Research Evidence / Overview of Studies for Пентаса (Mesalazine)

This section summarizes the structure of the available clinical research for mesalazine, focusing on what was studied and what was reported, without providing individual medical advice or making claims about guaranteed results.

---

Evidence for Inducing Disease Inactivity in Active Ulcerative Colitis

Research has explored the use of mesalazine in patients with active Ulcerative Colitis (UC), particularly those with mild-to-moderate disease activity. The foundational evidence is derived from short-term, controlled studies, known as Randomized Controlled Trials (RCTs), where the mesalazine preparation was studied alongside a non-active comparator (placebo) over defined time intervals. These studies were conducted during periods of increased symptom activity, which are conditions characterized by fluctuating or episodic manifestations.

Researchers monitored several outcomes related to acute changes in the condition. Trials measured the physical appearance of the colon lining (endoscopic healing) to assess the status of the internal inflammation. What the research so far indicates is that trials consistently described that differences were observed in the proportion of patients achieving defined clinical endpoints, such as changes in symptoms, between the groups receiving mesalazine and the groups receiving placebo over the short-term study period. Findings describe patterns observed in these studies where specific symptom measures showed changes during the typical 8- to 12-week observation phase.

---

Evidence for Maintaining Long-Term Disease Inactivity (Remission)

Once symptoms have stabilized and disease inactivity has been reached, research was studied for its use in long-term management, exploring the goal of sustained disease control. Long-term studies and comprehensive meta-analyses explored the consistency of these patterns over months or years. Research scenarios involved patient populations who were already in a quiescent (inactive) phase of Ulcerative Colitis.

---

Consistency of Evidence and Research Gaps

While a significant volume of research exists, findings and evidence quality varies across studies, leading to certain areas that remain uncertain.

• Long-Term Impact: There is limited information for long-term outcomes on factors such as sustained corticosteroid-free remission over many years, as these require very long observation periods that are not established in all trials.
• Formulation Equivalence: Comparative evidence is lacking to definitively state whether all different specialized delivery formulations of mesalazine are interchangeable in their long-term effects for every individual patient. Study results reflect the specific conditions under which they were conducted, and research does not determine whether an individual will respond similarly to a change in formulation.

Common questions about Пентаса (FAQ)

---

Q: Do I need to take Пентаса indefinitely?

Official information describes this medicine as a long-term treatment (maintenance therapy) used to help keep bowel inflammation under control and prevent flare-ups. The duration of use is typically extended to maintain remission in chronic conditions. The duration of treatment is determined by the healthcare provider.

Q: How quickly does Пентаса usually start to show an effect?

The mechanism of action begins upon administration to deliver its anti-inflammatory action directly to the intestinal lining. However, it may take several weeks before a patient notices visible improvement in their symptoms. The initial studies exploring its effectiveness typically observed patients over an 8- to 12-week period.

Q: What is the purpose of the outer coating on the Пентаса tablet?

This medicine uses a specialized controlled-release formulation involving ethylcellulose-coated microgranules. This coating is designed to ensure that the active ingredient, mesalamine, is released gradually and consistently throughout the entire length of the gastrointestinal tract. This targeted release is designed to deliver the anti-inflammatory action directly to the inflamed areas.

Q: What are the signs of an allergic reaction to Пентаса?

Regulatory safety documents note the risk of severe hypersensitivity reactions, also known as acute intolerance syndrome. Signs of this can include a sudden fever, headache, and rash. It may also present as a worsening of the underlying condition's symptoms, such as severe abdominal pain or bloody diarrhea. The presence of these signs is typically a matter for immediate clinical attention.

Q: Does Пентаса treat the cause or just the symptoms of the condition?

Mesalazine is classified as an anti-inflammatory agent that works to modulate the chronic inflammation driving the condition. By interfering with the chemical signals that cause inflammation in the gut wall, the drug's action is fundamentally mechanism-based. It is described as working to modulate the underlying disease activity, rather than merely relieving symptoms like pain.

Q: Are there different strengths of Пентаса tablets available?

Yes, the oral prolonged-release forms of the medication are available in various unit strengths. For example, the extended-release capsules are commonly available in 250 mg and 500 mg options. Dosage determination is established by the healthcare provider.

Q: Is Пентаса considered an immunosuppressant?

Official pharmacological classifications describe Mesalazine as an Aminosalicylate (5-ASA) anti-inflammatory agent. This is a class distinct from other medications, such as Azathioprine, which are generally referred to as immunosuppressants or immunomodulators. Its mechanism focuses on local anti-inflammatory action in the gut wall.

Q: Can Пентаса be stopped if symptoms disappear completely?

Official patient guidance is clear: abrupt cessation is generally not recommended, even if symptoms improve or disappear, as stopping treatment can increase the risk of the condition returning. Changes to the treatment schedule are decisions made in consultation with the prescribing physician.

Q: What happens if I forget to take a dose of Пентаса?

Labeling information provides directions for missed doses, indicating that it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the patient should simply skip the missed one. The product labeling specifies that a double dose should not be taken.

Q: Does taking Пентаса cause hair loss?

Hair loss (alopecia) has been reported in official documents based on postmarketing experience. This means it is generally considered a rare adverse reaction. Any new or concerning physical observation is a matter for clinical discussion.

Q: Can people with pre-existing heart conditions take Пентаса?

Regulatory safety data reports that rare cardiac hypersensitivity reactions, such as myocarditis and pericarditis, have occurred with mesalazine use. Caution is advised, and monitoring of the patient's condition is noted as an important consideration. A healthcare provider should evaluate any pre-existing heart conditions before treatment begins.

Q: Can Пентаса be taken with food, or is it better on an empty stomach?

Official prescribing information states that the oral extended-release capsules can generally be taken with or without food. The controlled-release design is intended to deliver the active ingredient throughout the digestive tract regardless of meal timing.

Q: Is Пентаса a steroid?

No. Mesalazine is an Aminosalicylate (5-ASA) drug, which has a distinct chemical structure and mechanism of action. Steroids (corticosteroids) are a separate class of drugs sometimes used to treat acute flare-ups of inflammatory bowel disease, often in combination with mesalazine.

Q: Is it normal to see tablet remnants in stool after taking Пентаса?

Official postmarketing safety information documents that 'stool abnormalities,' including changes in color or texture, have been reported. This phenomenon is sometimes seen with controlled-release medications whose outer shell is designed to pass after the active drug has been released. Any unusual physical observations are matters for discussion with a healthcare provider.

Q: How soon after starting Пентаса should I expect a follow-up appointment?

Regulatory guidance strongly emphasizes the need for laboratory monitoring, particularly for kidney and liver function tests. Specific testing timeframes are established shortly after treatment initiation. Subsequent monitoring is typically performed periodically thereafter, if initial results remain normal.

Q: What should I do if my symptoms worsen while taking Пентаса?

Official safety information indicates that a worsening of symptoms, which may relate to the acute intolerance syndrome, is a reason for immediate medical consultation. This may include increased abdominal cramping, fever, or bloody diarrhea.

Q: Can Пентаса be used as a monotherapy for inflammatory bowel disease?

Yes. Official clinical summaries support the use of Mesalazine as the first-line treatment for maintaining remission in patients with ulcerative colitis. Its primary role in long-term management often involves its use as a stand-alone therapy (monotherapy) once the condition has been stabilized.

How to Store and Dispose of Pentasa (Mesalamine)

The official storage requirements for Pentasa are strictly defined to maintain product stability and safety.

Storage Conditions

The medication must be stored at a temperature that does not exceed 30 C. The product must be protected from light and kept in its original container, with the lid tightly closed. It is specifically required that Pentasa must not be frozen.

Child Safety: A mandatory requirement is to keep Pentasa out of the sight and reach of children.

Stability Note: Prolonged-release granules, if applicable, must be used immediately after the first opening of the sachet.

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local requirements. The medication should not be disposed of via wastewater or routine household waste, reinforcing the need to follow specific regulatory disposal procedures.